The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Emerging Technologies for Low‐Cost, Rapid Vaccine Manufacture
Abstract
To stop the spread of future epidemics and meet infant vaccination demands in low‐ and middle‐income countries, flexible, rapid and low‐cost vaccine development and manufacturing technologies are required. Vaccine development platform technologies that can produce a wide range of vaccines are emerging, including: a) humanized, high‐yield yeast recombinant protein vaccines; b) insect cell‐baculovirus ADDomer vaccines; c) Generalized Modules for Membrane Antigens (GMMA) vaccines; d) RNA vaccines. Herein, existing and future platforms are assessed in terms of addressing challenges of scale, cost, and responsiveness. To assess the risk and feasibility of the four emerging platforms, the following six metrics are applied: 1) technology readiness; 2) technological complexity; 3) ease of scale‐up; 4) flexibility for the manufacturing of a wide range of vaccines; 5) thermostability of the vaccine product at tropical ambient temperatures; and 6) speed of response from threat identification to vaccine deployment. The assessment indicated that technologies in the order of increasing feasibility and decreasing risk are the yeast platform, ADDomer platform, followed by RNA and GMMA platforms. The comparative strengths and weaknesses of each technology are discussed in detail, illustrating the associated development and manufacturing needs and priorities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Design and development of polymers for gene delivery
Pack, D. W., Hoffman, A. S., Pun, S., & Stayton, P. S. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1775 · Cited by 2,568
Tools for translation: non-viral materials for therapeutic mRNA delivery
Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799 · cited 1×
“RNA vaccines are currently being tried clinically [103,104].”
BackgroundAdvances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
Oivanen, M., Kuusela, S., & Lönnberg, H. (1998) · Chemical Reviews · doi:10.1021/cr960425x · Cited by 438
Kuhn, A. N., Diken, M., Kreiter, S., Selmi, A., Kowalska, J., Jemielity, J., Darzynkiewicz, E., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Gene Therapy · doi:10.1038/gt.2010.52 · Cited by 226
Research works printed but not linked: 110
- 10.1016/j.vaccine.2017.06.003 · DOI · Paper page
- 10.1586/14760584.2013.850035 · DOI
- Qadri F., 2012, GAVI Alliance Partner's Forum
- 10.1371/journal.pone.0057755 · DOI · Paper page
- Wilson P., 2010, Giving Developing Countries the Best Shot: An Overview of Vaccine Access and R & D
- Datla M., 2012, GAVI Alliance Partner's Forum
- Wen E. P., 2015, Vaccine Development and Manufacturing
- 10.1080/14760584.2016.1205492 · DOI
- 10.1002/9781118636817 · DOI · Paper page
- 10.1155/2015/504831 · DOI
- Kallerup R. S., 2015, Subunit Vaccine Deliv, 15, 10.1007/978-1-4939-1417-3_2 · doi:10.1007/978-1-4939-1417-3_2
- Bloom B. R., 2016, The Vaccine Book
- Meyer H.‐P., 2017, Ind. Biotechnol. Prod. Process
- 10.1016/j.biologicals.2014.05.007 · DOI · Paper page
- 10.1007/978-1-4615-0053-7 · doi:10.1007/978-1-4615-0053-7
- 10.1586/14760584.2015.1067144 · DOI
- 10.1080/21645515.2016.1260795 · DOI
- 10.1016/S0958-1669(00)00197-X · DOI · Paper page
- 10.1002/3527602356.ch12 · doi:10.1002/3527602356.ch12
- Yang H., 2015, Pept. Protein Vaccines, 1
- 10.3389/fimmu.2018.00884 · DOI
- 10.1038/s41598-017-13069-w · DOI
- 10.1002/biot.201400427 · DOI
- 10.3389/fimmu.2018.00345 · DOI
- 10.1002/biot.201600598 · DOI
- 10.1002/biot.201700443 · DOI
- 10.1002/biot.201700749 · doi:10.1002/biot.201700749
- 10.1038/298347a0 · DOI · Paper page
- 10.1093/jnci/djj144 · DOI
- Kirnbauer R., 1993, J. Virol, 67, 6929, 10.1128/jvi.67.12.6929-6936.1993 · DOI
- 10.4161/hv.6.5.11023 · DOI
- 10.1016/j.vaccine.2016.10.016 · DOI
- 10.3389/fimmu.2014.00121 · DOI · Paper page
- 10.4161/hv.24129 · DOI · Paper page
- 10.1179/2047773214Y.0000000162 · DOI
- 10.1128/JVI.75.9.4040-4047.2001 · DOI · Paper page
- 10.3390/vaccines2040785 · doi:10.3390/vaccines2040785
- 10.2174/1872215611307010009 · doi:10.2174/1872215611307010009
- 10.1002/vms3.65 · doi:10.1002/vms3.65
- 10.1016/j.vaccine.2008.11.045 · doi:10.1016/j.vaccine.2008.11.045
- 10.1128/AEM.02817-12 · DOI
- 10.1038/nrmicro1087 · DOI · Paper page
- 10.1093/bfgp/elv041 · DOI
- 10.1007/s10529 · doi:10.1007/s10529
- 10.1371/journal.pone.0037915 · DOI
- 10.1371/journal.pone.0075347 · DOI
- 10.4161/bioe.22856 · DOI · Paper page
- 10.1038/nprot.2008.213 · DOI · Paper page
- 10.1016/j.jbiotec.2008.12.015 · DOI · Paper page
- 10.1016/j.pep.2004.03.019 · doi:10.1016/j.pep.2004.03.019
- 10.1016/j.copbio.2007.09.001 · DOI · Paper page
- 10.1016/0264-410X(90)90221-7 · DOI
- 10.1016/0168-1656(91)90264-V · doi:10.1016/0168-1656(91)90264-v
- 10.1038/nmeth983 · DOI · Paper page
- Berger I., 2013, J. Vis. Exp, 50159
- 10.1016/j.vaccine.2012.01.016 · DOI · Paper page
- 10.1016/j.vaccine.2014.07.074 · DOI
- 10.1073/pnas.1705836114 · DOI
- 10.1128/JVI.67.8.4566-4579.1993 · DOI · Paper page
- 10.1080/21655979.2015.1104433 · doi:10.1080/21655979.2015.1104433
- Sari D., 2016, Adv. Exp. Med. Biol, 199
- C. Geisler H. Mabashi‐Asazuma D. L. Jarvis A. Castilho 2015 Springer New York New York NY 131 · DOI
- 10.4161/bioe.22327 · doi:10.4161/bioe.22327
- 10.1371/journal.pone.0034226 · DOI
- D. Sari K. Gupta D. B. T. G. Raj A. Aubert P. Drncová F. Garzoni D. Fitzgerald I. Berger M. C. Vega 2016 Springer International Publishing Cham 199 · DOI
- 10.1038/nbt1036 · DOI · Paper page
- 10.1128/JVI.07127-11 · doi:10.1128/jvi.07127-11
- 10.1073/pnas.72.1.93 · DOI · Paper page
- 10.1128/JVI.76.17.8682-8689.2002 · DOI
- Kulp A., 2012, Annu Rev Microbiol, 163
- 10.1002/biot.201400395 · DOI · Paper page
- 10.1002/pmic.200900338 · DOI · Paper page
- 10.1073/pnas.1008843107 · DOI · Paper page
- 10.1172/JCI44261 · DOI · Paper page
- 10.1007/s00792-008-0199-x · DOI · Paper page
- 10.1371/journal.pone.0134353 · DOI
- 10.1371/journal.pone.0134478 · DOI · Paper page
- 10.1016/j.micres.2014.09.006 · DOI · Paper page
- 10.1073/pnas.0805532107 · DOI · Paper page
- 10.1016/j.vaccine.2014.03.068 · DOI
- 10.1016/j.vaccine.2010.04.082 · DOI · Paper page
- 10.1371/journal.pone.0065157 · doi:10.1371/journal.pone.0065157
- 10.1021/pr301208g · DOI
- 10.1016/j.smim.2013.05.004 · DOI
- 10.1074/jbc.M114.566570 · DOI
- 10.1016/j.jbiotec.2015.01.020 · doi:10.1016/j.jbiotec.2015.01.020
- 10.1016/j.vaccine.2016.11.089 · DOI
- 10.1371/journal.pone.0035616 · DOI
- N. Pardi H. Muramatsu D. Weissman K. Karikó P. M. Rabinovich 2013 Humana Press Totowa NJ 29 · DOI · Paper page
- 10.1016/j.ymthe.2017.03.023 · DOI · Paper page
- 10.1016/j.omtn.2017.06.005 · DOI · Paper page
- 10.14304/SURYA.JPR.V4N7.5 · DOI · Paper page
- 10.1016/S0264-410X(99)00271-6 · DOI · Paper page
- 10.3390/vaccines1030225 · DOI · Paper page
- 10.1016/j.ymthe.2017.11.017 · DOI · Paper page
- 10.1586/14760584.2015.965690 · DOI
- 10.1517/17425247.2014.901308 · DOI · Paper page
- 10.1016/j.nano.2015.11.001 · DOI
- 10.1016/j.jconrel.2017.09.018 · DOI
- 10.1155/2015/794528 · DOI · Paper page
- 10.1093/nar/gkn342 · DOI · Paper page
- Brito L. A., 2015, Nonviral Vectors Gene Ther, 179
- 10.1093/nar/gkw551 · DOI · Paper page
- Nigel A., 2013, J. Chem. Technol. Biotechnol, 89, 1283
- 10.1016/j.csbj.2016.06.007 · DOI
- 10.1099/jmm.0.039180-0 · DOI
- 10.1371/journal.pone.0111827 · DOI
- 10.1039/C4CC05086J · DOI
- World Health Organization inImmun. Pract. A Pract. Guid. Heal. Staff − 2015 Updat. Non‐Serial Publ. World Health Organization ISBN: 9241549092 9789241549097 2015 pp.1.
- 10.1016/j.vaccine.2016.11.097 · DOI
Cited by
The clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
mRNA vaccines manufacturing: challenges and bottlenecks
Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M., & Marques, M. P. C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.038 · Cited by 545
Edible packaging: Sustainable solutions and novel trends in food packaging
Trajkovska Petkoska, A., Daniloski, D., D'Cunha, N. M., Naumovski, N., & Broach, A. T. (2021) · Food Research International · doi:10.1016/j.foodres.2020.109981 · Cited by 473
Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376
Emerging Concepts and Technologies in Vaccine Development
Brisse, M., Vrba, S. M., Kirk, N., Liang, Y., & Ly, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583077 · Cited by 323
Metadata
- Authors
- Kis, Z., Shattock, R., Shah, N., & Kontoravdi, C.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2018-12-10
- Volume
- 14
- Issue
- 1
- Pages
- 1-2
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2903668992
- Cited by
- 207
- References
- 6
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Engineering and Physical Sciences Research Council (EP/R013764/1)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging Technologies for Low‐Cost, Rapid Vaccine Manufacture. https://app.cochat.ai/papers/10.1002/biot.201800376
- The paper
- Kis, Z., Shattock, R., Shah, N., & Kontoravdi, C. (2019). Emerging Technologies for Low‐Cost, Rapid Vaccine Manufacture. Biotechnology Journal. https://doi.org/10.1002/biot.201800376
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.